Thepaut Eric Francis Yves
Known title: EVP & Pres, Eur, Mid-East, AfrCIK: 0001631992
Associated companies
Transaction History
| BSX | ▲ Buy | Option Exercise | 12,931 | $211K | 5/10/2024 | View on chart |
| BSX | ▼ Sell | Open Market | 12,931 | $959K | 5/10/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,002 | $0 | 2/18/2024 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,160 | $76K | 2/18/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,500 | $0 | 2/17/2024 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,448 | $95K | 2/17/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,263 | $0 | 2/16/2024 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,311 | $86K | 2/16/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,379 | $0 | 2/14/2024 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,378 | $91K | 2/14/2024 | View on chart |
| BSX | ▲ Buy | Grant | 20,000 | $0 | 2/6/2024 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 11,579 | $0 | 2/6/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 13,080 | $0 | 1/1/2024 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 7,573 | $438K | 1/1/2024 | View on chart |
| BSX | ▲ Buy | Option Exercise | 30,688 | $396K | 5/2/2023 | View on chart |
| BSX | ▼ Sell | Open Market | 83,401 | $4.4M | 5/2/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,714 | $0 | 2/21/2023 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 993 | $46K | 2/21/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,001 | $0 | 2/18/2023 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,159 | $54K | 2/18/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,500 | $0 | 2/17/2023 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,448 | $67K | 2/17/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,262 | $0 | 2/16/2023 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,310 | $61K | 2/16/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,846 | $0 | 2/15/2023 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,069 | $51K | 2/15/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 7,092 | $0 | 1/1/2023 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 3,988 | $185K | 1/1/2023 | View on chart |
| BSX | ▼ Sell | Open Market | 14,952 | $639K | 11/18/2022 | View on chart |
| BSX | ▼ Sell | Open Market | 20,676 | $848K | 8/1/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,833 | $0 | 2/28/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,031 | $46K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,714 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 964 | $41K | 2/21/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,001 | $0 | 2/18/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,125 | $48K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,500 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,406 | $60K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,846 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,038 | $46K | 2/15/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 6,175 | $0 | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 3,472 | $147K | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.